KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Current Taxes (2016 - 2025)

Pfizer (PFE) has disclosed Current Taxes for 17 consecutive years, with $3.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, Current Taxes rose 6.63% to $3.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $3.1 billion, a 6.63% increase, with the full-year FY2025 number at $3.1 billion, up 6.63% from a year prior.
  • Current Taxes was $3.1 billion for Q4 2025 at Pfizer, down from $3.8 billion in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $4.5 billion in Q4 2021 to a low of $1.3 billion in Q4 2021.
  • A 5-year average of $2.7 billion and a median of $2.9 billion in 2023 define the central range for Current Taxes.
  • Peak YoY movement for Current Taxes: soared 214.41% in 2021, then crashed 38.2% in 2023.
  • Pfizer's Current Taxes stood at $1.3 billion in 2021, then increased by 25.36% to $1.6 billion in 2022, then surged by 48.02% to $2.3 billion in 2023, then grew by 23.88% to $2.9 billion in 2024, then rose by 6.63% to $3.1 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Current Taxes are $3.1 billion (Q4 2025), $3.8 billion (Q3 2025), and $3.7 billion (Q2 2025).